Suppr超能文献

左心耳封堵术:预防心房颤动卒中的经皮导管介入治疗方法。

Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation.

机构信息

Cardiology, Cardiovascular Center, University Hospital Zurich, Raemistrassse 100, 8091 Zurich, Switzerland.

出版信息

Eur Heart J. 2012 Mar;33(6):698-704. doi: 10.1093/eurheartj/ehr393. Epub 2011 Oct 31.

Abstract

Atrial fibrillation is a frequent cause of stroke; in the elderly, more than 20% of strokes are attributed to this common arrhythmia. Anticoagulation with warfarin reduces the risk of stroke by ∼60%; however, a large proportion of patients with atrial fibrillation do not receive this treatment because of relative/absolute contraindications. Moreover, patients often discontinue warfarin for a variety of reasons and chronic warfarin administration rates remain suboptimal. Although the compliance with anticoagulation may improve with novel anticoagulants and bleeding risk can be somewhat reduced when compared with warfarin, there is still a progressive increase in bleeding complications over time. Accordingly, new approaches for stroke prevention in these patients are being explored and tested. In transoesophageal echocardiographic (TEE) studies, more than 90% of thrombi were found in the left atrial appendage (LAA) in non-valvular atrial fibrillation, and transcatheter LAA closure is developed and examined as a novel approach to reduce the risk of stroke in these patients. The PROTECT-AF study provides first evidence from a randomized clinical trial that a strategy of LAA occlusion using the Watchman device can be non-inferior to anticoagulation with warfarin for a combined endpoint in patients with non-valvular atrial fibrillation (mean CHADS(2) score 1.8). In successfully occluded patients fulfilling TEE criteria (86%), warfarin was stopped after 45 days, followed by aspirin and clopidogrel for 6 months after randomization and subsequently aspirin. The PREVAIL trial is further evaluating this concept. Limited data are available for another LAA occlusion system, the Amplatzer Cardiac Plug (ACP) device, for which the ACP trial has been initiated. Left atrial appendage occlusion needs to be performed with meticulous care by experienced operators because periprocedural complications such as pericardial effusion or stroke have been documented. With increased operator experience and technical improvements of the device, these complications can be minimized.

摘要

心房颤动是中风的常见原因;在老年人中,超过 20%的中风归因于这种常见的心律失常。华法林抗凝可降低中风风险约 60%;然而,由于相对/绝对禁忌证,很大一部分心房颤动患者未接受这种治疗。此外,由于各种原因,患者经常停止服用华法林,且慢性华法林治疗率仍不理想。尽管与华法林相比,新型抗凝剂可提高抗凝治疗的依从性,且出血风险可略有降低,但随着时间的推移,出血并发症仍呈逐渐增加趋势。因此,正在探索和测试这些患者的中风预防新方法。在经食管超声心动图(TEE)研究中,超过 90%的非瓣膜性心房颤动患者的血栓位于左心耳(LAA),经导管 LAA 封堵术作为一种降低这些患者中风风险的新方法得到开发和检验。PROTECT-AF 研究首次提供了一项随机临床试验的证据,表明使用 Watchman 装置的 LAA 封堵策略在非瓣膜性心房颤动患者(平均 CHADS2 评分 1.8)的复合终点方面可与华法林抗凝相媲美。在符合 TEE 标准的成功封堵患者(86%)中,在随机分组后 45 天停用华法林,然后在随机分组后 6 个月使用阿司匹林和氯吡格雷,随后使用阿司匹林。PREVAIL 试验正在进一步评估这一概念。另一种 LAA 封堵系统 Amplatzer 心脏塞(ACP)装置的相关数据有限,ACP 试验已经启动。需要由经验丰富的操作者进行精心的左心耳封堵,因为已记录到围手术期并发症,如心包积液或中风。随着操作者经验的增加和设备技术的改进,这些并发症可最小化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验